补充剂对妊娠糖尿病的疗效:随机对照试验的元分析
Liwei Luo1, Yu Zhang1, HongMan Wang1
1Department of endocrinology, Chongqing general Hospital, China.
European journal of obstetrics, gynecology, and reproductive biology
|December 21, 2023
概括
补充剂通过降低禁食血葡萄糖和胰岛素耐药性,显著改善妊娠糖尿病的血糖控制. 它显示出作为妊娠糖尿病治疗的潜力,特别是对于那些不需要胰岛素的人来说.
科学领域:
- 产科和妇科 产科和妇科
- 内分泌学 在内分泌学.
- 营养科学 营养科学
背景情况:
- 对于治疗妊娠糖尿病 (GDM) 的有效性仍然不确定.
- 孕期糖尿病对母亲和胎儿的健康构成风险,需要有效的管理策略.
- 了解矿物质补充在GDM中的作用对于改善妊娠结果至关重要.
研究的目的:
- 评估补充剂在改善妊娠糖尿病妇女的血糖控制方面的疗效.
- 评估补充剂对母亲和胎儿怀孕关键结果的影响.
- 通过元分析综合随机对照试验 (RCT) 的证据.
主要方法:
- 在主要数据库 (PubMed, EMbase, Web of Science, EBSCO, Cochrane Library) 进行系统的文献搜索,截至2023年7月.
- 包括五项随机对照试验 (RCT),涉及266名被诊断患有妊娠糖尿病的患者.
- 使用基于数据异质性的随机效应或固定效应模型进行的元分析.
主要成果:
- 补充剂显著降低了禁食血葡萄糖 (FPG) 水平 (MD = -7.33 mg/dL; P < 0.00001).
- 通过HOMA-IR测量胰岛素耐药性,在补充时显著下降 (MD = -0.99; P = 0.01).
- 没有观察到对血清胰岛素水平,早产,巨视或BMI变化的显著影响.
结论:
- 补充似乎是改善妊娠糖尿病妇女的血糖控制的有效策略.
- 益处最明显在于降低禁食葡萄糖和胰岛素抵抗.
- 可能是妊娠糖尿病的宝贵辅助疗法,特别是在不需要胰岛素治疗的情况下.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Pathophysiology of Diabetes
944
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
944
Hypoglycemia and Glucagon
266
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
266
Oral Hypoglycemic Agents: Biguanides and Glitazones
207
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
207
Dipeptidyl Peptidase 4 Inhibitors
189
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
189
Diabetes: Management and Pharmacotherapy
288
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
288


